| Filed On | Filing |
|---|---|
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Completion of Acquisition or Disposition of Assets
Reported favorable safety, tolerability and pharmacokinetic (“PK”) results from the single ascending-dose portion of the TX2100 Phase 1a clinical trial in healthy adult volunteers; FDA granted TX2100 Fast Track designation for Hereditary... |
| 29 Oct 2026 | SCHEDULE 13G/A |
| 28 Oct 2026 |
Form 4: Reicin Alise, Director
Received 10,000 shares by exercise or conversion ($23.8K) |
| 02 Oct 2026 |
Form 4: Lochner Daniel, Chief Financial Officer
Gave up 520 shares to cover exercise price or tax ($12.3K) |
| 02 Oct 2026 |
Form 4: McNamara Peter, Chief Scientific Officer
Gave up 444 shares to cover exercise price or tax ($10.5K) · Sold 536 shares ($12.3K) |
| 02 Oct 2026 |
Form 4: Ruddy Marcella K., Chief Medical Officer
Gave up 525 shares to cover exercise price or tax ($12.4K) |
| 02 Oct 2026 |
Form 4: Reicin Alise, Director
Gave up 1,545 shares to cover exercise price or tax ($36.6K) |
| 02 Oct 2026 |
Form 4: Schwabish Marc, Chief Business Officer
Gave up 411 shares to cover exercise price or tax ($9.73K) |
| 30 Sep 2026 | 144 |
| 29 Sep 2026 |
8-K: Other Events
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) |
| 08 Sep 2026 |
Form 4: Schwabish Marc, Chief Business Officer
Granted 17,750 Employee Stock Option (Right to Buy) |
| 08 Sep 2026 |
Form 4: McNamara Peter, Chief Scientific Officer
Granted 21,000 Employee Stock Option (Right to Buy) |
| 08 Sep 2026 |
Form 4: Lochner Daniel, Chief Financial Officer
Granted 24,250 Employee Stock Option (Right to Buy) |
| 08 Sep 2026 |
Form 4: Ruddy Marcella K., Chief Medical Officer
Granted 24,250 Employee Stock Option (Right to Buy) |
| 08 Sep 2026 |
Form 4: Reicin Alise, Director
Granted 69,250 Employee Stock Option (Right to Buy) |
| 27 Aug 2026 | 144 |
| 26 Aug 2026 |
Form 4: McNamara Peter, Chief Scientific Officer
Received 43 shares by exercise or conversion ($633) · Sold 43 shares ($1.57K) |
| 21 Aug 2026 | 144 |
| 14 Aug 2026 |
Form 4: McNamara Peter, Chief Scientific Officer
Received 43 shares by exercise or conversion ($633) · Sold 43 shares ($1.51K) |
Loading...